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SUMMARY
Mammary ductal dysplasia is a phenotype observed in precancerous lesions and early-stage breast
cancer. However, the mechanism of dysplasia formation remains elusive. Here we show, by establish-
ing a novel dysplasia model system, that estrogen, a female hormone, has the potential to causemam-
mary ductal dysplasia.We injected estradiol (E2), themost active formof estrogen, daily into scidmice
with a defect in non-homologous end joining repair and observed dysplasia formation with cell prolif-
eration at day 30. The protooncogene Myc is a downstream target of estrogen signaling, and we
found that its expression is augmented in mammary epithelial cells in this dysplasia model. Treatment
with a Myc inhibitor reduced E2-induced dysplasia formation. Moreover, we found that isoflavones
inhibited E2-induced dysplasia formation. Our dysplasia model system provides insights into the
mechanistic understanding of breast tumorigenesis and the development of breast cancer prevention.
INTRODUCTION
During breast tumorigenesis, mammary ductal dysplasia is observed in precancerous lesions and early-
stage breast cancers. Mammary ductal dysplasia exhibits a loss of the biphasic mammary epithelial andmy-
oepithelial pattern, an abnormal nucleus, epithelial cell expansion, a disruption in the myoepithelial cell
layer, and/or mammary epithelial cell invasion to fibrous stroma, whereas a normal mammary duct main-
tains cell polarization, the biphasic pattern, and the smooth luminal surface of the mammary epithelial
cell layer. Given that dysplasia can progress to malignant neoplasms (Arpino et al., 2005; Cichon et al.,
2010; Sgroi, 2010), elucidating the mechanism of dysplasia formation will contribute to the prevention of
breast tumorigenesis.
Previous studies have established various breast cancer mouse models by genetic engineering. For
example, the mammary gland-specific expression of c-neu (Her2/ErbB2), polyoma middle T antigen,
and Wnt-1 causes breast cancer (Guy et al., 1992; Li et al., 2000; Muller et al., 1988). Mice with a mutation
in Tp53, a tumor suppressor gene, also developed breast cancer (Kuperwasser et al., 2000). Although these
models have provided knowledge about breast cancer, particularly at an advanced stage, they have not
been primarily used for studies on mammary ductal dysplasia observed in precancerous lesions and
early-stage breast cancers. Previous dysplasia studies in mice used radiation in ataxia telangiectasia
mutated heterozygous mice (Weil et al., 2001) and the overexpression of constitutively activated Smooth-
ened receptor (Moraes et al., 2007) and of the oncogene nuclear receptor-binding SET domain protein
3 (Turner-Ivey et al., 2017). Because studies using genetically engineered mice have been designed to
examine phenotypes specifically caused by the functions of their target genes and these studies could
not provide knowledge about the relationships between the factors involved, thesemodels are not suitable
to elucidate the molecular mechanism by which mammary ductal dysplasia is naturally formed. To under-
stand such a mechanism of dysplasia formation, a mouse model that forms dysplasia by physiological fac-
tor(s) and facilitates the mechanistic understanding of dysplasia formation is required.
Estrogen, a female hormone, promotes the development of the normal mammary duct and the prolifera-
tion of breast cancer (reviews Deroo and Korach, 2006; Heldring et al., 2007; Liang and Shang, 2013; Man-
avathi et al., 2013). There are a number of studies on the function of estrogen in breast cancer (reviews Burns
and Korach, 2012; Deroo and Korach, 2006; Liang and Shang, 2013; Manavathi et al., 2013; Siersbæk et al.,
2018). Although estrogen is thought to be involved in breast tumorigenesis in epidemiologic studies (Dall
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Figure 1. Estrogen Administration Induces Mammary Ductal Dysplasia in scid Mice
(A) DNA double-strand breaks were detected in MCF-7 cells. PRKDC was knocked down. Gamma-H2AX was
immunostained. Numbers of gH2AX foci per cell were graphed (jitter plot). Black dots indicate mean values. Data were
obtained from 2 or 3 independent experiments (total 200–520 cells in each group, U Mann-Whitney test).
(B) Messenger RNA levels of GREB1, TFF1, and MYC were quantified (n = 3 experiments, one-way ANOVA followed by
Tukey’s test). Cells were treated with or without E2 for 6 h.
(C) Gamma-H2AX-positive mammary epithelial cells were detected and quantified at 6, 9, and 12 h after E2 administration
(n = 3 mice in wild-type [WT] + E2 0 h, 6 h, 9 h, 12 h and scid + E2 0 h, 6 h, 9 h, 12 h; n = 4 mice in scid + E2 + fulvestrant 6 h,
one-way ANOVA followed by Tukey’s test).
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and Britt, 2017; Kelsey et al., 1993) and a combination of radiation and E2 treatment transformed normal
mammary cells in vitro (Calaf and Hei, 2000), there is no experimental evidence showing that estrogen re-
ceptor a (ERa)-mediated estrogen signaling induces mammary dysplasia from normal mammary epithelial
cells in vivo.
Estrogen regulates gene expression via the activation of ERa. In mammary glands, ERa is expressed mainly
in mammary epithelial cells. Although there are various functional models of ERa action, in the classical
mechanism of ERa, estrogen-bound ERa forms a dimer, localizes in the nucleus, and binds to its DNA-bind-
ing site to regulate gene expression (reviews Arnal et al., 2017; Burns and Korach, 2012; Heldring et al.,
2007; Maggi, 2011; Yasxar et al., 2017). Thus far, various ERa-regulated genes have been identified (Liang
and Shang, 2013; Manavathi et al., 2013; Siersbæk et al., 2018); these include growth regulating estrogen
receptor-binding 1 (GREB1), trefoil factor 1 (TFF1, pS2), andmyelocytomatosis (MYC) (Barkhem et al., 2002;
Lin et al., 2004; Wang et al., 2011).Myc expression is associated with poor survival in breast cancer (Deming
et al., 2000; Green et al., 2016). Myc (c-Myc) is also involved in breast cancer proliferation (Hart et al., 2014;
Liao and Dickson, 2000; Liao et al., 2000). During ERa-mediated gene regulation, a DNA double-strand
break is made at the promoter of a target gene to promote its expression (Ju et al., 2006; Williamson
and Lees-Miller, 2011). Whether ERa-mediated gene regulation with a DNA double-strand break is
involved in dysplasia formation remains unclear. In this study, we successfully established a novel dysplasia
model system and investigated the mechanism of dysplasia formation.
RESULTS
Enhancement of ERa-Mediated Estrogen Signaling Causes Mammary Ductal Dysplasia
To investigate E2-induced DNA damage in vitro, we treated an ERa-positive breast cancer cell line, MCF-7,
with or without estradiol (E2), the most active form of estrogen, for 2 h and counted the number of the sig-
nals of phosphorylated-histone H2AX (gamma-H2AX, gH2AX), a marker of DNA double-strand breaks (Fig-
ure S1A). The number of gH2AX signals was increased by E2 treatment and reduced by cotreatment with
fulvestrant, an estrogen receptor inhibitor (Figure S1A), indicating that E2 treatment causes DNA double-
strand breaks via its receptor. An inhibitor of DNA-dependent protein kinase (DNA-PK), NU-7441, inhibits
non-homologous end joining repair, one of the repair mechanisms of DNA double-strand breaks (Leahy
et al., 2004). NU-7441 cotreatment did not change the number of gH2AX signals after 2-h E2 treatment (Fig-
ure S1A), indicating that the loss of DNA-PK function does not change E2-generated DNA damage under
our conditions.
To determine whether estrogen-induced DNA double-strand breaks are involved in the regulation of the
downstream genes of estrogen signaling, we reduced the capacity of non-homologous end joining by
knocking down PRKDC, which encodes the catalytic subunit of DNA-PK (Davis et al., 2014). Cells were
washed with medium in the absence of E2 after 2-h E2 treatment to analyze repair capacity. No increase
in the number of gH2AX signals was observed in control cells (Figure 1A), indicating that cells were allowed
to repair E2-induced DNA double-strand breaks during 2 h after washing out E2 under our conditions.
However, larger number of the gH2AX signals were observed after washing in PRKDC-knockdown cells
than in control cells (Figures 1A and S1B), suggesting that the loss of DNA-PK function delays the repair
of E2-induced DNA double-strand breaks. Long-lived DNAbreaks (unrepaired at least 12 h after DNA dam-
age induction) are believed to be involved in transcriptional regulation, at least in specific cases (Puc et al.,
2017). To investigate the expression of ERa downstream genes under our conditions, mRNA levels were
Figure 1. Continued
(D) Typical images of H&E staining are shown. Daily injection of E2 was performed for 30 days. The table shows ratios of
dysplasia (n = 6 mice [one image from each mouse, total six images], WT + E2 4.49%, scid + PBS 2.07% [p = 0.274, versus
WT + E2], and scid + E2 16.58% [p = 0.002, versus WT + E2], U Mann-Whitney test).
(E) Typical immunostaining images of CK5 are shown. The table shows ratios of disruption (n = 6 mice [one image from
eachmouse, total six images], WT + E2 0.92%, scid + PBS 0.52% [p = 1.00, versusWT + E2], and scid + E2 5.23% [p = 0.041,
versus WT + E2], U Mann-Whitney test).
(F) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion
were quantified (n = 10 mice in WT + E2, scid + PBS and scid + E2 groups, n = 6 mice in scid + E2+Fulv. group, one-way
ANOVA followed by Tukey’s test and U Mann-Whitney test). Fulv., fulvestrant. Scale bars, 10 mm in (A) and 30 mm in (C–F).
n.s., not significant, *p < 0.05, **p < 0.01. Error bars represent standard deviation. Arrowheads indicate mammary
epithelial cells in extraductal region (D–F). In the graphs, crosses with different colors indicated the values of different
samples (B) and animals (C and F).
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quantified in cells with or without 6-h E2 treatment (Figure 1B). PRKDC knockdown increased GREB1
expression in untreated cells. In E2-treated groups, the expression of GREB1 was enhanced following
PRKDC knockdown. The expression of TFF1 was not altered by PRKDC knockdown. Interestingly, after
E2 treatment, we observed 2-fold higherMYC expression in PRKDC-knockdown cells than in control cells.
We treated cells with NU-7441 and L189, an inhibitor for ligases I, III, and IV, to reduce the capacity of
non-homologous end joining (Figure S1D). Ligases I, III, and IV are involved in DNA repair including
non-homologous end joining. In cells treated with these inhibitors, higher Myc expression was observed
after E2 stimulation than in DMSO-treated control cells (Figure S1E). These results suggest that a reduction
in the repair capacity of DNA double-strand breaks enhances MYC expression in response to E2
stimulation.
We injected E2 (6 mg/mouse) intraperitoneally into scid mice with a genetic defect in DNA-PK catalytic sub-
unit function (Bosma et al., 1983; Kirchgessner et al., 1995). The serum concentration of E2 was transiently
increased and reduced to the background level after 6 h in both wild-type and scid mice (Figure S1C). The
results of gH2AX staining showed an increased number of gH2AX-positive mammary epithelial cells (Fig-
ure 1C). As expected, scid mice showed a larger number of gH2AX-positive cells than wild-type mice at 6 h
(5-fold larger) and 9 h (3-fold larger) after E2 administration. No increase in the number of gH2AX-positive
mammary epithelial cells was observed at 9 h in wild-type and at 12 h in scid mice, suggesting that E2-
induced DNA double-strand breaks were repaired at these time points, and E2 administration transiently
induced DNA double-strand breaks under our conditions. Increase in the number of gH2AX-positive mam-
mary epithelial cells was not observed in mice administered E2 and fulvestrant.
To investigate whether long-term E2 administration could cause an abnormality in the mammary gland, we
performed consecutive daily injections of E2 for 30 days. No significant change in body weights was
observed after 30 days of injection (Figure S2A). Hematoxylin and eosin (H&E) staining showed normal
mammary ducts in both wild-type and scid mice at day 7 (Figure S2B). At day 30, whereas E2-injected
wild-type (WT + E2) and phosphate-buffered saline (PBS)-injected scid (scid + PBS) mice exhibited normal
mammary ducts (Figure 1D), dysplasia formation (i.e., increased cell number, loss of the biphasic mammary
epithelial and myoepithelial pattern, and epithelial cell expansion to the outside of a duct) was observed in
E2-injected scid mice (scid + E2) (Figures 1D and S2C). To examine whether mammary ducts with dysplasia
had disrupted basement membrane, we coimmunostained for Laminin, the component of basement mem-
brane, and CK8, the mammary epithelial cell marker. Some mammary ducts with dysplasia showed disrup-
ted basement membrane andmammary epithelial cell invasion (Figure S2D). Because human breast cancer
shows disruption in the myoepithelial layer (Cichon et al., 2010), we immunostained cells for the myoepi-
thelial cell markers cytokeratin 5 (CK5) (Figure 1E) and p63 (Figure S2E). We observed a disruption in the
myoepithelial layers in mammary ducts with dysplasia. To determine whether mammary epithelial cells
of the ducts with dysplasia invaded the outside of the myoepithelial layer, coimmunostaining of CK5
and CK8 was performed (Figure 1F). The results revealed mammary ducts with increased mammary epithe-
lial cell numbers and the loss of the biphasic pattern (Figure 1F intraductal) and mammary ducts with
epithelial cells in the extraductal region with a disruption in the CK5 cell layer (Figure 1F extraductal) in
scid + E2. As terminal end buds are epithelial cell-rich regions that can be identified as a duct with no
fibrous stroma region (Sternlicht, 2006) and as it is difficult to distinguish dysplasia from normal terminal
end buds, these were excluded in the analyses. We analyzed the frequency of dysplasia formation and
observed significant increases in both intraductal and extraductal expansion (Figure 1F graph, Table S1).
A duct with both intraductal and extraductal expansion was counted as a duct with extraductal expansion.
These results suggest that repetitive E2 administration induces mammary ductal dysplasia in scid mice.
Coadministration with the estrogen receptor inhibitor (scid + E2 + Fulv.) showed no increase in the fre-
quency of dysplasia, suggesting that the suppression of estrogen receptor function may prevent dysplasia
formation in a DNA repair-deficient condition. ERa expression was observed in mammary epithelial cells in
both normal and dysplastic ducts (Figure S2F). ERa positivity was not only difference between PBS and E2
administration but also between normal and dysplastic ducts in scid mice.
We coadministered NU-7441, a DNA-PK inhibitor, and E2 to two wild-type strains, C.B17/Icr and C57BL/6J.
C.B17/Icr is the parental strain of scid mice. C57BL/6J is a commonly used strain. At day 30, we observed an
increase in dysplasia formation in NU-7441 + E2 mice compared with NU-7441 + PBS mice in both strains
(Figure S3 and Table S1). This result indicates that E2 administration can induce mammary ductal dysplasia
not only in scid mice but also in wild-type strains with induced DNA repair defect.
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Progesterone Inhibits E2-Induced Dysplasia Formation
Progesterone (PG), a female hormone, alters ERa chromatin binding events in malignant breast cancer
through progesterone receptor (PGR), which changes gene expression patterns, and the administration
of PG reduced E2-dependent tumor growth in mouse xenograft experiments with MCF-7 cells (Mo-
hammed et al., 2015). To determine whether PG-activated PGR inhibits E2-induced DNA double-strand
breaks in MCF-7 cells, we performed a combination treatment of E2 and PG for 4 h with or without PGR
knockdown (Figures 2A and 2B). The number of gH2AX signals was increased by E2 treatment but not
by the combination of E2 and PG (Figure 2B). In PGR-knockdown cells, the combination treatment of E2
and PG resulted in increased number of gH2AX signals, similar to E2 treatment, suggesting that PGR pre-
vents E2-induced DNA double-strand breaks.
Figure 2. Progesterone Inhibits Estrogen-Induced Mammary Ductal Dysplasia
(A) Progesterone receptor (PGR) gene was knocked down (n = 3 experiments, Student’s t test to shScr control).
(B) DNA double-strand breaks were detected by gH2AX immunostaining. Numbers of gH2AX foci per cell were analyzed
(jitter plot) (n = 3 independent experiments, total 380–520 cells in each group, U Mann-Whitney test).
(C) Typical images of H&E staining are shown. The table shows ratios of dysplasia (n = 6 mice [one image from each
mouse, total six images], E2 13.96% and E2 + PG 6.69% [p = 0.038, versus E2], U Mann-Whitney test).
(D) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion
were quantified (n = 8 mice, U Mann-Whitney test).
Scale bars, 10 mm in (B) and 30 mm in (C and D). n.s., not significant, *p < 0.05, **p < 0.01. Error bars represent standard
deviation. Arrowheads indicate mammary epithelial cells in extraductal region (C and D). In the graphs, crosses with
different colors indicated the values of different samples (A) and animals (D).
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Figure 3. Estrogen Administration Promotes Mammary Epithelial Cell Proliferation in scid Mice
(A) PCNA-positive mammary epithelial cells were detected at day 30. Ratios of the positive cells were analyzed (n = 6mice
in WT + E2 and scid + E2 + Fulv. groups, and n = 8 mice in scid + PBS and scid + E2 groups, one-way ANOVA followed by
Tukey’s test).
(B) Ki-67-positive mammary epithelial cells were detected. Ratios of the positive cells were analyzed (n = 6 mice, one-way
ANOVA followed by Tukey’s test).
(C) PCNA-positive cells were analyzed in day 7 mice (n = 6 mice in WT + E2 and scid + E2 groups, and n = 3 in scid + PBS
group, one-way ANOVA followed by Tukey’s test).
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The function of PG in dysplasia formation in vivo remains elusive. To this end, we coinjected E2 and PG into
our dysplasia model system. In scid mice at day 30, the administration of E2 alone caused dysplasia forma-
tion, and the coadministration of E2 and PG prevented dysplasia formation (Figure 2C). Double immuno-
staining for CK5 and CK8 showed that PG administration prevented extraductal expansion (Figure 2D). The
quantification of intraductal and extraductal expansion showed that PG reduced the frequencies of these
abnormalities (Figure 2D). These results suggest that PG has a protective effect against E2-induced DNA
damage and dysplasia formation in a DNA-repair-deficient condition.
Estrogen Promotes Mammary Epithelial Cell Proliferation
As the number of CK8-positive cells was likely increased in scid + E2 mice (Figure 1F), we investigated cell
proliferation by immunostaining for proliferating cell nuclear antigen (PCNA), an S-phase marker, and Ki-
67, a proliferation marker, at day 30 (Figures 3A and 3B). The results of immunostaining showed that the
ratio of proliferating mammary epithelial cells was increased 1.5-fold in scid + E2 mice, and this increase
was inhibited by the ERa inhibitor (scid + E2+Fulv.). An increased number of proliferating cells was also
observed at day 7 (Figures S4 and 3C). To investigate organ-level changes, we visualized mammary ducts
with carmine alum staining at day 30 (Figure 3D). Themammary glands of scid + E2mice weremore densely
distributed than those of the control mice and exhibitedmore small branches. The number of branches was
increased in scid + E2 mice compared with control mice (Figure 3D graph). These results suggest that E2
administration induces cell proliferation in the mammary glands of scid mice.
E2-Induced Myc Expression Causes Mammary Ductal Dysplasia
We hypothesized that one of the causes of dysplasia is the E2-induced expression of ERa downstream
genes. Our in vitro experiments showed that E2 administration has the potential to increase the expression
of a protooncogene, MYC (Figure 1B). In a previous study, mice with enhanced Myc expression exhibited
mammary cell proliferation and an increase in branching (Tseng et al., 2014), similar to our observation in
scid + E2 mice (Figure 3). We therefore focused on Myc. The results of Myc mRNA in situ hybridization
showed that althoughMycmRNA expression was increased at 2 h after E2 injection in the mammary ducts
of both wild-type and scid mice, scid mice had stronger signals than did wild-typemice (Figure S5A). In scid
mice, Myc mRNA expression was still clearly observed at 6 and 9 h and faintly at 12 and 24 h, whereas the
signal was not observed at 6 h onward in wild-type mice (Figure S5A). In the results of gH2AX staining (Fig-
ure 1C), the number gH2AX-positive mammary epithelial cells were transiently increased at 6 and 9 h in scid
mice. These results suggest that E2-induced double-strand breaks may promote Myc expression, but not
elongateMyc expression for longer periods. A significant increase in the number of Myc-positive mammary
epithelial cells was observed in scid mice at 6 h and day 30 (Figures 4A and S5B). This increase was not
observed following the coadministration of E2 and fulvestrant or PG (Figure 4A). These results indicate
that E2 administration increases Myc expression in vivo.
To determine whether estrogen signaling promotesMYC expression in human breast cancer, we analyzed the
expression of Myc mRNA and ERa protein in a tissue microarray with human breast tissues. Myc mRNA was
observed in the cytoplasm, and ERa was localized in the nucleus (Figure 4B). We observed Myc and ERa dou-
ble-positive cells in the samples of hyperplasia, ductal carcinoma in situ, and invasive ductal carcinoma. Because
of intratumoral heterogeneity, there were alsoMyc-positive ERa-negative,Myc-negative ERa-positive, andMyc
and ERa double-negative cells. We analyzed the ratio ofMyc-positive tissues in ERa-negative and ERa-positive
malignant breast cancers, andMycpositivity was higher in ERa-positive tissues than in ERa-negative tissues (Fig-
ure 4B graph, negative 43.58% versus positive 93.10%). In Myc-positive ERa-positive tissues, 26 of 27 samples
had Myc and ERa double-positive cells (96.29%). These observations suggest that estrogen signaling may be
involved in the modulation ofMyc expression in human breast cancer.
We coadministered E2 and the Myc inhibitor KJ-Pyr-9 (Hart et al., 2014), in scid mice, to investigate
the involvement of Myc in dysplasia formation. We observed around a 2-fold reduction in the ratio of
Figure 3. Continued
(D) Carmine alum staining was performed in mammary ducts of day 30 mice. Numbers of branches in 9 mm2 area close to
lymph node were counted (n = 10 mice in WT + E2, scid + PBS, and scid + E2 groups, n = 6mice in scid + E2 + Fulv. group,
one-way ANOVA followed by Tukey’s test). Fulv., fulvestrant.
Scale bars, 30 mm in (A–C) and 2 mm in (D). *p < 0.05, **p < 0.01. Error bars represent standard deviation. In the graphs,
crosses with different colors indicated the values of different animals.
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Figure 4. Estrogen-Induced Myc Expression Promotes Mammary Epithelial Cell Proliferation and Dysplasia
Formation
(A) Typical images ofMyc immunostaining are shown. Ratios ofMyc-positivemammary epithelial cells are analyzed (n= 6mice in
WT + E2 and scid + E2, n = 4 mice in scid + E2 + Fulv. and scid + E2 + PG, one-way ANOVA followed by Tukey’s test).
(B) Typical images of the combination of MYC in situ hybridization and ERa immunostaining are shown. Arrowheads
indicate MYC-expressing ERa-positive cells. MYC positivity was analyzed in the samples from malignant tumors (n = 39
ERa-negative and 29 ERa-positive samples, Fisher’s exact test).
(C) PCNA was detected in mammary glands of mice treated with or without an Myc inhibitor, KJ-Pyr-9. Ratio of PCNA-
positive cells were quantified (n = 6 mice, Student’s t test).
(D–F) Typical images of carmine alum staining are shown. Numbers of branches in 9 mm2 area close to lymph node were
counted (n = 6 mice, Student’s t test). (E) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with
intraductal and extraductal expansion were quantified (n = 6 mice, U Mann-Whitney test). Arrowheads indicate mammary
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PCNA-positive mammary epithelial cells by Myc inhibition compared with the DMSO control at day 30 (Fig-
ure 4C). At the organ level, the number of branching points was also reduced (Figure 4D). These results
indicate that Myc inhibition leads to reduced E2-induced cell proliferation in the mammary gland in scid
mice.
Ductal dysplasia was investigated with H&E staining and immunostaining for CK5 and CK8 at day 30. Most
mammary ducts (96.04%) were normal in the Myc inhibitor-administered group (Figure S5C). Moreover, in-
traductal and extraductal expansion was significantly reduced following administration of the Myc inhibitor
(Figure 4E). The Myc inhibitor did not alter ERa positivity (Figure S5D). These results indicate that E2-
induced Myc expression is one of the causes of mammary ductal dysplasia (Figure 4F).
Isoflavones Prevent E2-Induced Dysplasia Formation
Our dysplasia model system can be utilized to study breast cancer prevention. Isoflavones are flavonoids
and are rich in soybean. Epidemiological studies have suggested that isoflavones have a protective effect
against breast cancer (Fritz et al., 2013). Genistein, an isoflavone, inhibited breast cancer cell growth (Shao
et al., 1998). On the other hand, a study using breast cancer cells showed that genistein promoted tumor
growth (Hsieh et al., 1998). E2 and isoflavones bound to estrogen receptors competitively, and isoflavone
binding reduced estrogen receptor-mediated gene expression in vitro (Morito et al., 2001). Therefore, the
effect of isoflavones in breast cancer is still controversial. To address this issue, we investigated the effect of
isoflavones in our dysplasia model system. We used two isoflavones, (S)-equol and genistein. When E2-
induced DNA double-strand breaks were analyzed, both isoflavones reduced E2-induced DNA damage
(Figure 5A). MYC mRNA quantification showed that isoflavones reduced MYC expression 1.4-fold under
E2-treated conditions compared with treatment with E2 alone, although its expression level was higher
than in the PBS control (Figure 5B). These results suggest that isoflavones have the potential to reduce
E2 function.
The coadministration of E2 and isoflavones reduced the proliferation of mammary epithelial cells in scid
mice at day 30 (Figures 5C and S6A). The number of branches was reduced by isoflavones (Figures 5D
and S6B). These results suggest that isoflavones are effective at preventing E2-induced cell proliferation.
H&E staining showed that most of the mammary ducts of mice coadministered E2 and isoflavones had
normal ductal structures and retained the biphasic mammary epithelial and myoepithelial pattern at day
30 (Figure 5E). The results of CK5 and CK8 immunostaining showed that the ratio of intraductal and extra-
ductal expansion was reduced by isoflavone administration (Figure 5F). These results indicate that isofla-
vones have the potential to prevent E2-induced dysplasia formation in scid mice.
To investigate whether PG and isoflavones work in the same pathway to prevent dysplasia formation, we
performed combination treatments of E2, PG, and isoflavones. In the results of gH2AX staining at 6 h,
administration of PG and isoflavones in combination with E2 did not show increase in the number of
gH2AX-positive mammary epithelial cells (Figures 5G and S6C). Myc positivity was reduced in the mice
administered E2 + isoflavones, although the positivity was higher than control at 6 h (Figures 5H and
S6D). This observation is consistent with our in vitro assays (Figure 5B). E2 + PG administration showed a
comparable Myc positivity with control (Figure 4A). Combination treatment of E2 + PG + isoflavones
also showed a similar Myc positivity to the control. These results suggest that although both PG and iso-
flavones can reduce E2-induced DNA double-strand breaks, the inhibitory mechanism of Myc expression
was not the same.
Progesterone, Myc Inhibitor, and Isoflavones Have a Potential to Prevent Mammary Ductal
Dysplasia Formation in Wild-Type Mice
To investigate the effects of PG, KJ-Pyr-9, (S)-equol, and genistein in wild-type mice without DNA repair
deficiency, we coadministered E2 and these materials to C57BL/6J mice for 30 days. In the results of
CK8 and CK5 double staining (Figure 6), mice administered E2 alone showed slight increase in the
Figure 4. Continued
epithelial cells in extraductal region. (F) E2-induced Myc expression causes mammary ductal dysplasia in scid mice.
Fulv.: fulvestrant, KJ, KJ-Pyr-9.
Scale bars, 30 mm in (A, C, and E), 10 mm in (B), and 2 mm in (D). *p < 0.05, **p < 0.01. Error bars represent standard
deviation. In the graphs, crosses with different colors indicated the values of different animals.
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Figure 5. Isoflavones Inhibit Dysplasia Formation by Preventing the Function of Estrogen in scid Mice
(A) DNA double-strand breaks were detected by gH2AX immunostaining. Numbers of gH2AX foci per cell were analyzed
(jitter plot) (n = 3 independent experiments, total 550–670 cells in each group, U Mann-Whitney test).
(B) MYC mRNA levels were quantified in MCF-7 cells (n = 3 experiments, one-way ANOVA followed by Tukey’s test).
(C) Ratios of PCNA-positive cells were analyzed (n = 6 mice, one-way ANOVA followed by Tukey’s test).
(D) Numbers of branches were analyzed in carmine alum-stained mammary glands (n = 6 mice, one-way ANOVA followed
by Tukey’s test).
(E) Typical images of H&E staining are shown. The table shows ratios of dysplasia (n= 6mice [one image from eachmouse,
total six images), PBS 2.42%, E2 14.90% [p = 0.002, versus PBS], E2 + Eq. 3.76% [p = 0.445, versus PBS], and E2 + Ge. 4.39%
[p = 0.445, versus PBS], U Mann-Whitney test).
(F) Fluorescent images of CK8 and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion
were quantified (n = 6 mice in scid + PBS, scid + E2 + Eq., and scid + E2 + Ge. groups, n = 5 mice in scid + E2, one-way
ANOVA followed by Tukey’s test and U Mann-Whitney test).
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frequencies of intraductal and extraductal expansion, although the changes were not statistically signifi-
cant between mice administered PBS and E2. This slight increase was prevented by coadministration
with PG, KJ-Pyr-9, (S)-equol, and genistein. These results suggest that PG, Myc inhibitor, and isoflavones
may have a potential to prevent E2-induced mammary ductal dysplasia.
DISCUSSION
We demonstrated E2-induced mammary ductal dysplasia in mice, providing direct evidence that estrogen
causes mammary ductal dysplasia. This study showed that E2 administration in scid mice enhances Myc
expression, which promotes dysplasia formation. In humans, long-term estrogen exposure has the poten-
tial to cause breast cancer (Dall and Britt, 2017; Kelsey et al., 1993). On the other hand, DNA repair capacity
is not maintained throughout life (Kalfalah et al., 2015; Li et al., 2016). In the breast, human mammary
epithelial cells from aged donors were more sensitive to mammography-induced DNA damage than cells
from young donors (Herna´ndez et al., 2013). Mammary epithelial cells from older women showed a delay in
DNA double-strand break repair, compared with those from younger women (Anglada et al., 2019). Muta-
tions in genes related to the DNA damage response/repair lead to the risk of developing breast cancer
(Miki et al., 1994; Stankovic et al., 1998). Our dysplasia-inducing model system (i.e., 30-day E2 injection
in mice with reduced DNA repair capacity) may mimic some of the situations of human breast tissue that
are susceptible to mammary ductal dysplasia.
Although our dysplasia model uses an excess amount of E2 and mice with reduced DNA repair capacity, it
will be useful to investigate the mechanism of dysplasia formation and to develop a method for dysplasia
prevention. By using this system, we revealed that Myc is one of the causes of dysplasia formation. How-
ever, one question that remains is why does E2 promote Myc expression and cell proliferation in almost
all parts of a mammary gland but dysplasia occurs in only a small portion. To address this question, the
identification of other factors is required, which may be facilitated with our dysplasia model system.
Although Myc expression alone is not sufficient to develop malignant breast tumors (Stewart et al.,
1984; Tseng et al., 2014), given that Myc overexpression induces a replicative stress and stress-associated
diseases, including cancer (Murga et al., 2011), E2-inducedMYC expression may be an early event in breast
tumorigenesis. In addition, we showed dysplasia formation in wild-type strains by coadministration of the
DNA-PK inhibitor and E2. These results indicate that our dysplasia model system can be utilized in various
strains and genetically engineered mouse models, such as Tp53-knockout mice.
We observed that the number of DNA double-strand breaks and Myc expression were increased in scid
mice at 6 and 9 h after E2 administration. DNA double-strand breaks were repaired at 12 h. On the other
hand, in scid mice, E2 administration did not immediately promote mammary epithelial cell proliferation,
and the proliferation was observed at day 7. These results suggest that E2-induced DNA double-strand
breaks and Myc expression are not directly involved in the initiation of cell proliferation, or in addition
to Myc expression, mammary epithelial cell proliferation requires unidentified factor(s), which works at
day 7 in our model system.
It is considered that breast cancer metastasizes in a very early stage in some cases (Fisher, 1980; Fisher
et al., 1981), which causes distant metastasis andmetastatic recurrence. Given that microinvasion is an early
event in metastasis, inhibition of microinvasion in a very early stage may reduce breast cancer mortality.
E2-induced dysplasia observed in this study showed microinvasion. Administration of Myc inhibitor or
isoflavones inhibited it. These results suggest that our dysplasia model system can be utilized to study
very-early-stage breast cancer for metastasis prevention.
For the breast cancer prevention study, we showed the first experimental evidence that isoflavones in-
hibited E2-induced dysplasia formation in a DNA repair-deficient condition. Although our dysplasia
Figure 5. Continued
(G) Ratios of gH2AX-positive mammary epithelial cells were analyzed (n = 3 mice, one-way ANOVA followed by Tukey’s
test).
(H) Ratios of Myc-positive mammary epithelial cells were analyzed (n = 3 mice, one-way ANOVA followed by Tukey’s test).
Eq, (S)-equol, Ge., genistein.
Scale bars, 10 mm in (A) and 30 mm in (E and F). *p < 0.05, **p < 0.01. Error bars represent standard deviation. Arrowheads
indicate mammary epithelial cells in extraductal region (E and F). In the graphs, crosses with different colors indicated the
values of different samples (B) and animals (C, D, and F–H).
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model system does not mimic all kinds of breast cancer types, our findings suggest that isoflavones can
be utilized to prevent breast cancer. In the future, this dysplasia induction model system may contribute
to the understanding of breast cancer tumorigenesis and to the development of breast cancer
prevention.
Limitation of the Study
Our dysplasia model system is a model for estrogen-induced dysplasia, but not for dysplasia caused by
other factors, implying that our findings contribute to the understanding of the tumorigenesis of some
breast cancer types, although early stages of most breast cancer types exhibit dysplasia with similar
morphological changes.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100821.
Figure 6. Progesterone, Myc Inhibitor, and Isoflavones Have a Potential to Reduce Mammary Dysplasia
Formation
C57BL/6J mice were administered E2 in combination with PG, KJ, Eq. or Ge. for 30 days. Fluorescent images of CK8
and CK5 staining are shown. Mammary ducts with intraductal and extraductal expansion were quantified (n = 6 mice,
one-way ANOVA followed by Tukey’s test and U Mann-Whitney test). Scale bars, 30 mm. Error bars represent standard
deviation. In the graphs, crosses with different colors indicated the values of different animals. Eq., (S)-equol; Ge.,
genistein; KJ, KJ-Pyr-9.
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MCF-7 cells were obtained from the American Type Culture Collection (Manassas, VA, 
USA). Short tandem repeat analysis was performed for cell authentication in July 2017 
and the result showed no contamination and no alteration. Mycoplasma contamination 
was checked every 3 months by staining with Hoechst 33342 (Dojindo, 346-07951, 
Kamimashiki, Japan, 1/500 dilution) and no contamination was observed. Cells were 
maintained in Roswell Park Memorial Institute 1640 (RPMI-1640) medium containing 
10% heat-inactivated fetal bovine serum (FBS), 100 units/mL Penicillin, 100 μg/mL 
Streptomycin and 1nM β-estradiol (E2) (Sigma, E2758, St. Louis, MO, USA) at 37℃ 
with 5% CO2. To obtain G1 phase cells For gH2AX staining experiments, cells were 
starved with phenol-red-free FBS-free RPMI-1640 medium containing 100 units/mL 
Penicillin and 100 μg/mL Streptomycin for 24 h. E2, progesterone (PG) (Sigma, P8783), 
(S)-equol (Cayman Chemical, 10010173, Ann Arbor, MI, USA) and genistein (Nagara 
Science, NH010302, Gifu, Japan) were solved in ethanol, diluted with PBS and added to 
medium (final concentration: 10 nM). Fulvestrant (Sigma, I4409) was solved with ethanol, 
diluted with PBS and added to medium (final concentration: 100 nM). NU-7441 (AdooQ 
Bioscience, A11098, Irvine, CA, USA) was solved in DMSO, diluted with PBS and added 
to medium (final concentration: 0.5 μM). For mRNA quantification of ERα downstream 
genes, cells were cultured with phenol-red-free RPMI-1640 medium containing 10% 
charcoal-stripped FBS, 100 units/mL Penicillin and 100 μg/mL Streptomycin for 48 h, 
subsequently treated with or without 10 nM E2 for 6 h. 
 
Loss of function study 
For short hair-pin RNA (shRNA) expression, a lentiviral vector pLKO.1 (Addgene, 8453, 
Cambridge, MA, USA) was used. Double-strand DNA oligo with shRNA sequence was 
cloned into the region between AgeI and EcoRI sites of the vector. The target sequences 
were 5'-CCAGTGAAAGTCTGAATCATT-3' (shPRKDC #2), 5'-
CCTGAAGTCTTTACAACATAT-3' (shPRKDC #4), 5'-
GCTGCTGGAAGACGAAAGTTA-3' (shPGR #1) and 5'-
CAATACAGCTTCGAGTCATTA-3' (shPGR #2). Control shRNA was 5'-
CCTAAGGTTAAGTCGCCCTCG-3' (shScr). 
 Lentiviral vector was cotransfected with lentiviral envelope and packaging 
 3 
plasmids, pMDLg/pRRE (Addgene, 12251), pMD2.G (Addgene, 12259) and pRSV-Rev 
(Addgene, 12253) at a ratio of 2.5:1.0:0.6:0.5 into Lenti-X 293T cells (Takara, 632180, 
Kusatsu, Japan). The transfection reagent, FuGENE 6 (Promega, E2691, Madison, WI, 
USA) was used. Lenti-X 293T cells were maintained with Dulbecco's modified Eagle 
medium containing 10% FBS, 100 units/mL Penicillin and 100 μg/mL Streptomycin. One 
day after transfection, medium was changed to the medium for MCF-7 cells and incubated 
for 24~30 h. Medium containing lentiviral particles was filtered (0.22 μm pore size), 
added to MCF-7 cell culture with 6 μg/mL polybrene and incubated for 48 h. For drug 
selection to obtain infectants, cells were treated with 1 μg/mL puromycin for 4 days. 
 
Messenger RNA quantification 
Cells were cultured in 6-well plate or 6 cm dish. Cells were rinsed with cold PBS and 
treated with 300 μL of Trizol reagent (Thermo Fisher Scientific, 15596018, Waltham, MA, 
USA). Sixty μL of chloroform was added, mixed and stand for 5 min. After centrifugation 
at 4℃, supernatant was collected and purified with PureLink RNA Micro Kit (Thermo 
Fisher Scientific, 12183016). 
 Five hundred ng of total RNA was used for complementary DNA (cDNA) 
synthesis. SuperScript III reverse transcriptase (Thermo Fisher Scientific, 18080044) was 
used. Synthesized cDNA was diluted with sterilized MilliQ water (1/10 dilution) for real-
time polymerase chain reaction (PCR). 
 Real-time PCR was performed with a reagent, FastStart Universal SYBR Green 
Master (Sigma, 04 913 850 001, St. Louis, MO, USA). Signals were detected by 
StepOnePlus real-time PCR system (Thermo Fisher Scientific, 4376600) with StepOne 
software ver2.2.2. 
 Primer sequences were: EF1A1 (internal control) forward: 5'- 
AAATGACCCACCAATGGAAGCAGC-3' reverse: 5'- 
TGAGCCGTGTGGCAATCCAATACA-3', PRKDC forward: 5'-
CGCCGTGTGAATATAAAGATTGG-3' reverse: 5'-
CGTGACTGTTTCAGTACGATTAG-3', GREB1 forward: 5'-
CTGCTGTACCTCTGTGACTCTT-3' reverse: 5'-GTCCTGACAGATGACACACAAC-
3', TFF1 forward: 5'-CCCTGGTCCTGGTGTCCAT-3' reverse: 5'-
AGCAGCCCTTATTTGCACACT-3', MYC forward: 5'-CTCGGATTCTCTGCTCTCCT-





Immunostaining in cell culture 
Cells were plated onto an 8-well chamber slide (Matsunami glass, SCS-N08, Kishiwada, 
Japan) with 400 μL medium, and cultured for 2 days. For fixation, a half of the medium 
was removed, and 200 μL of 4% paraformaldehyde (PFA) in PBS was added (final 2% 
PFA). After 10~15 min fixation at room-temperature, cells were washed with PBS 
containing 0.05% Tween-20 (PBS-T). Permeabilization was performed with PBS 
containing 0.1% Triton-X 100 for 15 min at room-temperature. Cells were washed with 
PBS-T twice. Blocking was performed with 5% goat serum-containing PBS-T for 1 h at 
room-temperature. Cells were incubated with primary antibody in blocking solution for 
overnight (15~20 h) at 4℃. Primary antibody was anti-gH2AX antibody (S139) (Cell 
Signaling Technology, 2577S, Danvers, MA, USA, 1/200 dilution). Cells were washed 
with PBS-T 3 times and incubated with secondary antibody in blocking solution for 1~2 
h at room-temperature. Secondary antibody was goat anti-rabbit IgG antibody conjugated 
to Alexa Fluor 546 (Life Technologies, A11010, 1/1000 dilution). Cells were washed with 
PBS twice and counterstained with Hoechst 33342 for 30 min at room-temperature. Cells 
were washed with PBS, dried and mounted with Fluoromount-G (SouthernBiotech, 0100-
01, Birmingham, AL, USA). 
 
Mouse experiments 
Female C.B17/Icr wild-type (C.B17/Icr-scidJcl +/+) and scid (C.B17/Icr-scidJcl 
scid/scid) mice were purchased from CLEA Japan (Tokyo, Japan) (6~8-week-old). Six-
week-old female C57BL/6J mice were purchased from Japan SLC (Hamamatsu, Japan). 
Mice were maintained under specific- pathogen-free condition. Intraperitoneal injection 
was performed with 30G needle in the morning. Injected reagents were E2 (6 μg/day), 
PG (6 μg/day), Fulvestrant (100 μg/day), NU-7441 (100 μg/day), KJ-Pyr-9 (Namiki Shoji, 
HY-19735, Tokyo, Japan, 0.2 mg/day), (S)-equol (6 μg/day) and genistein (6 μg/day). 
Mice were euthanized by cervical dislocation, and mammary glands were isolated. For 
30-day samples, mammary glands were isolated at 24 h after final injection. For 
measurement of E2 serum concentration after administration, 5-week-old female mice 
were ovariectomized to eliminate endogenous E2. After 5 weeks, E2 was injected 
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intraperitoneally, and blood samples were collected from tail vein. E2 concentration was 
measured by using E2 ELISA(EIA) kit (Calbiotech, ES180S-100, El Cajon, CA, USA), 
SPECTRA max 340PC (Molecular devices, San Jose, CA, USA) and SoftMax Pro 5.4 
(Molecular Devices). The animal experiments were approved by the Animal Research 
Committee of Kyoto University, number MedKyo17554 and MedKyo18321. All animals 
were maintained according to the Guide for the Care and Use of Laboratory Animals 
(National Institute of Health Publication). 
 
Immunostaining in mammary gland 
For cryo-section, isolated mammary gland was fixed with 4% PFA in PBS shortly (4 ℃, 
15 min, rocking). the sample was washed with PBS 3 times and incubated with 30% 
sucrose in PBS for 1~2 h at room-temperature. the sample was embedded in OCT 
compound (Sakura Finetek, 4583, Tokyo, Japan), and frozen with liquid nitrogen. Ten μm 
cryo-section was cut at -50℃, and dried. Dried section was fixed with 4% PFA for 3 min 
at room-temperature and rinsed with PBS. For paraffin-section, mammary gland was 
fixed with 10% formaldehyde neutral buffer solution for longer than 24 h at room-
temperature, dehydrated and embedded in paraffin. Three μm paraffin-section was de-
paraffinized, washed with PBS and rinsed with H2O. For heat-induced epitope retrieval, 
specimen was put into boiling sodium citrate buffer (10 mM sodium citrate, 0.05 % 
Tween-20, pH 6.0), incubated for 40 min and cooled for 20 min. 
 Specimen was washed with PBS-T 3 times and blocked with blocking solution 
(5% goat serum in PBS-T) for 1 h at room-temperature. Specimen was incubated with 
primary antibody in blocking solution for overnight (15~20 h) at 4 ℃. Primary antibodies 
were anti-gH2AX antibody (Cell Signaling Technology, 2577S, 1/200 dilution), anti-CK8 
antibody (Developmental Studies Hybridoma Bank, TROMA-I, Iowa City, IA, USA 
1/200 dilution), anti-CK5 antibody (Abcam, ab75869, 1/200 dilution), anti-Laminin 
antibody (Sigma, L9393, 1/500 dilution), anti-PCNA antibody clone PC10 conjugated to 
Alexa Fluor 647 (BioLegend, 307912, San Diego, CA, 1/20 dilution), anti-Ki-67 antibody 
D3B5 (Cell Signaling Technology, 12202S, 1/400 dilution), anti-c-Myc antibody (Abcam, 
ab32072, 1/200 dilution), anti-ERα antibody (Millipore, 06-935, 1/400 dilution) and anti-
ERα antibody SP1 (NeoMarkers, RM-9101-S0, Fremont, CA, USA, 1/100 dilution). 
Specimen was washed 3 times with PBS-T and incubated with secondary antibody in 
blocking solution. Secondary antibodies were biotinylated goat anti-rabbit IgG (Vector, 
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BA-1000, Burlingame, CA, USA, 1/200 dilution), goat anti-rat IgG conjugated to Alexa 
Fluor 488 (Cell Signaling Technology, 4416S, 1/1000 dilution) and goat anti-rabbit IgG 
antibody conjugated to Alexa Fluor 546 (Life Technologies, A11010, 1/1000 dilution).  
 For DAB colorimetric detection, after secondary antibody reaction, specimen 
was blocked with 3% H2O2 for 10 min, washed with PBS 3 times and incubated with 
ABC kit (Vector, PK-6101). Specimen was washed with PBS and rinsed with H2O. After 
DAB reaction, the specimen was washed with H2O and counterstained with hematoxylin. 
The specimen was rinsed with H2O and washed with H2O for 10 min. Dehydrated 
specimen was mounted with Malinol (Muto Pure Chemicals, 2009-1, Tokyo, Japan). 
 For immunofluorescence, after secondary antibody reaction, specimen was 
washed with PBS twice and counterstained with Hoechst 33342 for 30 min at room-
temperature. The specimen was washed with PBS, dried and mounted with Fluoromount-
G. In each animal, 3 or 4 sections were analyzed. 
 
Carmine Alum-staining 
Isolated mammary gland was fixed with 4% PFA for 2 h at 4℃, washed with PBS twice 
and washed with H2O. The sample was incubated with Carmine Alum staining solution 
(2 mg/mL carmine, 5 mg/mL aluminum potassium sulfate, a small amount of thymol) for 
overnight (20~24 h) at room-temperature. After staining, the sample was washed with 
70% ethanol for 1 h at room-temperature, 95% ethanol for 1 h at room-temperature and 
100% ethanol for 1 h at room-temperature. Subsequently the sample was cleared with 
xylene overnight (16~20 h) at room-temperature. Xylene was replaced to methyl 
salicylate for storage. One image was taken in each animal and numbers of branches in 9 
mm2 area close to lymph node were counted. 
 
In situ hybridization 
For probe synthesis, DIG RNA labeling kit (SP6/T7) (Roche, 11 175 025 910, Mannjeim, 
Germany) was used. The kit contains a vector, pSPT18, and RNA polymerases. A probe 
for mouse Myc mRNA was used (Itou et al., 2012). The coding sequence of human MYC 
gene was amplified from the cDNA sample of MCF-7 cells. Myc and MYC genes were 
cloned into the region between the HindIII and the EcoRI sites of the pSPT18 vector. 
Linearized Myc and MYC vectors were obtained by cutting with HindIII and PstI, 
respectively. T7 RNA polymerase was used. Synthesized RNA probe was purified and 
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diluted with hybridization solution (50% formamide, 5x SSC, 5x Denharts, 250 μg/mL 
yeast tRNA, 500 μg/mL salmon sperm DNA). 
 For cryo-section, section 18 μm thick was dried overnight. A 4 μm thick 
paraffin-section of the tissue microarray of human breast tissues obtained with patient's 
informed consent (US Biomax, BRC1502, Derwood, MD, USA) was purchased and de-
paraffinized. Investigations were performed according to the principles expressed in the 
Declaration of Helsinki. 
 Section was fixed with 4% PFA in PBS for 10 min at room-temperature and 
washed with PBS for 3 min 3 times. The section was treated with 2 μg/mL proteinase K 
in PBS for 10 min at room-temperature and fixed with 4% PFA in PBS for 5 min at room-
temperature. The section was washed with PBS for 3 min 3 times. For acetylation, the 
section was put into a solution (295 mL H2O, 4 mL triethanolamine and 0.525 mL HCl), 
then 0.75 mL acetic anhydrate was added, and mixed by dipping. After 10 min acetylation 
at room-temperature, the section was washed with PBS for 3 min 3 times. PBS was 
removed, and the section was incubated with hybridization solution for 1 h at room-
temperature. Probe solution (30 ng probe in 100 μL hybridization solution) was prepared, 
heated at 80℃ for 5 min, and iced. Hybridization was performed for overnight (18~20 h) 
at 68℃. 
 After hybridization, the section was washed with 5x SSC for 10 min at 65℃. 
Subsequently the section was washed with 0.2x SSC for 1 h at 65℃ 3 times, washed with 
0.2x SSC for 5 min at room-temperature and washed with TBS solution (0.1M Tris-HCl 
pH7.5, 0.15M NaCl) for 5 min at room-temperature. Blocking was performed with a 
blocking solution, 10% goat serum in TBS, for 1 h at room-temperature. After blocking, 
anti-DIG antibody conjugated to alkaline phosphatase (Roche, 11 093 274 910, 1/5000 
dilution) or anti-DIG antibody conjugated to Fluorescein (Roche, 11 207 741 910, 1/200 
dilution) was diluted in TBS solution containing 1% goat serum, and the section was 
incubated with the antibody solution at 4℃ for overnight (18~22 h). For combination 
with immunostaining, a primary antibody was added to the antibody solution. 
 For alkaline phosphatase colorimetric reaction, section was washed with TBS 
solution for 5 min at room-temperature 3 times. The section was equilibrated with a 
solution (0.1M Tris-HCl pH9.5, 0.1M NaCl, 0.05M MgCl2). Color development was 
performed with NBT/BCIP solution (Roche, 11 681 451 001) for 4~8 h at room-
temperature. Reaction was stopped by washing with PBS. The section was fixed with 4% 
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PFA in PBS for 20 min at room-temperature. The section was washed with H2O, dried 
and mounted with MX oil (Matsunami glass, FX00100). In mouse experiments, 3 or 4 
sections were analyzed in each animal. 
 For combination with in situ hybridization and immunostaining, after primary 
antibody reaction, the section was washed with PBS-T for 5 min 3 times. Incubated with 
secondary antibodies in 5% goat serum-containing PBS-T. Secondary antibody for in situ 
hybridization was anti-fluorescein/Oregon Green antibody conjugated to Alexa Fluor 488 
(Life technologies, A11096, 1/1000 dilution). The section was washed with PBS twice 
and counterstained with Hoechst 33342 for 30 min at room-temperature. The section was 
washed with PBS, dried and mounted with Fluoromount-G. 
 
Microscopy 
Images of H&E staining, immunostaining and in situ hybridization were collected at room 
temperature with an all-in-one microscope BZ-9000 (Keyence, Osaka, Japan) equipped 
with a 20x plan apochromatic objective lens (NA: 0.75), a x40 plan apochromatic lens 
(NA: 0.95) and a x100 plan apochromatic lens (NA: 1.40), and BZ-II Viewer software 
(Keyence). Hoechst 33342 signal was excited by 340-380 nm light and detected with 435-
485 nm light. Alexa Fluor 488 signal was excited by 450-490 nm light and detected with 
510-560 nm light. Alexa Fluor 546 signal was excited by 527.5-552.5 nm light and 
detected with 577.5-632.5 nm light. Alexa Fluor 647 signal was excited by 590-650 nm 
light and detected with 662.5-737.5 nm light. 
 Images of Carmine Alum-stained mammary glands were collected at room-




Numbers of gH2AX foci of cultured cells were counted manually and analyzed by U 
Mann-Whitney test. Delta Ct values of real-time PCR experiments were normalized by 
the mean values of the control groups and analyzed by student's t-test and one-way 
ANOVA followed by Tukey's test. Numbers of mammary epithelial cells having more 
than 5 gH2AX foci were counted manually and analyzed by one-way ANOVA followed 
by Tukey's test. Values of E2 serum concentration were normalized by the mean values 
of 0 h samples and analyze by student's t-test between wild-type and scid mice in each 
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time point. Numbers of mammary ducts with intraductal and extraductal expansion were 
analyzed by one-way ANOVA followed by Tukey's test and U Mann-Whitney test. 
Numbers of mammary epithelial cells having immunostaining signals of PCNA, Ki-67, 
Myc and ERα were counted manually, and analyzed by one-way ANOVA followed by 
Tukey's test and student's t-test. Numbers of branches were analyzed by one-way ANOVA 
followed by Tukey's test and student's t-test. MYC positivity of ERα negative and positive 
groups in the tissue microarray was analyzed by Fisher's exact test. P values are listed in 
Table S2. P<0.05 was considered to be statistically significant. 
 
Supplemental reference 
Itou, J., Kawakami, H., Quach, T., Osterwalder, M., Evans, S.M., Zeller, R., 
and Kawakami, Y. (2012). Islet1 regulates establishment of the posterior 
hindlimb field upstream of the Hand2-Shh morphoregulatory gene network 
in mouse embryos. Development (Cambridge, England) 139, 1620-1629. 
 
Key resource table 
Reagent or resource Source Identifier 
Antibodies 
gH2AX Cell Signaling Technology 2577S 
CK8 Developmental Studies 
Hybridoma Bank 
TROMA-I 
CK5 Abcam ab75869 
Laminin Sigma L9393 
PCNA BioLegend 307912 
Ki-67 Cell Signaling Technology 12202S 
c-Myc Abcam ab32072 
ERα Millipore 06-935 
ERα NeoMarkers RM-9101-S0 
Biological Samples 
Human breast tissue microarray US Biomax BRC1502 
Chemicals, Peptides, and Recombinant Proteines 
Hoechst 33342 Dojindo 346-07951 
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β-estradiol Sigma E2758 
Progesterone Sigma P8783 
(S)-equol Cayman Chemical 10010173 
Genistein Nagara Science NH010302 
Fulvestrant Sigma I4409 
NU-7441 AdooQ Bioscience A11098 
L189 Cayman Chemical 18374 
KJ-Pyr-9 Namiki Shoji HY-19735 
Critical Commercial Assays 
FuGENE 6 Promega E2691 
Trizol Thermo Fisher Scientific 15596018 
PureLink RNA Micro Kit Thermo Fisher Scientific 12183016 
SuperScript III Thermo Fisher Scientific 18080044 
FastStart Universal SYBR Green Master Sigma 04 913 850 001 
E2 ELISA(EIA) kit Calbiotech ES180S-100 
DIG RNA labeling kit Roche 11 175 025 910 
Experimental models: Cell lines 
MCF-7 ATCC HTB-22 
Lenti-X 293T Takara 632180 
Experimental models: Organisms/Strains 
Mouse: C.B17/Icr-scidJcl +/+ CLEA Japan N/A 
Mouse: C.B17/Icr-scidJcl scid/scid CLEA Japan N/A 
Mouse: C57BL/6J Japan SLC N/A 
Oligonucleotides 
Primer: EF1A1 forward 
AAATGACCCACCAATGGAAGCAGC 
This paper N/A 
Primer: EF1A1 reverse 
TGAGCCGTGTGGCAATCCAATACA 
This paper N/A 
Primer: PRKDC forward 
CGCCGTGTGAATATAAAGATTGG 
This paper N/A 
Primer: PRKDC reverse 
CGTGACTGTTTCAGTACGATTAG 
This paper N/A 
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Primer: GREB1 forward 
CTGCTGTACCTCTGTGACTCTT 
This paper N/A 
Primer: GREB1 reverse 
GTCCTGACAGATGACACACAAC 
This paper N/A 
Primer: TFF1 forward 
CCCTGGTCCTGGTGTCCAT 
This paper N/A 
Primer: TFF1 reverse 
AGCAGCCCTTATTTGCACACT 
This paper N/A 
Primer: MYC forward 
CTCGGATTCTCTGCTCTCCT 
This paper N/A 
Primer: MYC reverse 
TCTTCCTCATCTTCTTGTTCCTC 
This paper N/A 
Primer: PGR forward 
CACAGCGTTTCTATCAACTTACAA 
This paper N/A 
Primer: PGR reverse 
CCGGGACTGGATAAATGTATTC 
This paper N/A 
Recombinant DNA 
Plasmid: pLKO.1 Addgene 8453 
Plasmid: pMDLg/pRRE Addgene 12251 
Plasmid: pMD2.G Addgene 12259 
Plasmid: pRSV-Rev Addgene 12253 
Software and Algorithms 
ImageJ NIH https://imagej.
nih.gov/ij/ 
R R Development Core Team https://cran.r-
project.org/ 


































Figure S1 Estrogen administration induces DNA double-strand breaks. Related to 
Figure 1 
A, DNA double-strand breaks were detected in MCF-7 cells. Numbers of gH2AX foci 
per cell were graphed (jitter plot). Black dots indicate mean values (total 459~760 cells 
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NU-7441, a DNA-PK inhibitor. B, PRKDC gene was knocked-down (n=3 experiments, 
student's t-test to shScr control). MCF-7 cells were used. C, E2 serum concentration was 
measured (n=3 mice, student's t-test in each time point). D. Numbers of gH2AX foci per 
cell were graphed (jitter plot). Black dots indicate mean values (total 374~515 cells in 
each group, U Mann-Whitney test). Messenger RNA levels of GREB1, TFF1 and MYC 
were quantified (n=3 experiments, one-way ANOVA followed by Tukey's test). n.s.: not 
significant, **: P<0.01. Error bars represent standard deviation. In the graphs, crosses 































Figure S2 Long-term estrogen administration causes dysplasia. Related to Figure 1 
A, Body weight was measured at day 30 (n=10 mice, student's t-test). B, Images of H&E 
staining of mammary glands are shown. Mammary glands were isolated at day 7. The 
table shows ratios of dysplasia (n=6 mice (one image from each mouse, total 6 images), 




















































































































































Additional to Fig. 1D, H&E images of mammary glands of E2-administered scid mice 
are shown. Arrowheads indicate mammary epithelial cells in extraductal region. D, 
Basement membrane was stained with anti-Laminin antibody. Arrowheads indicate a 
region lost basement membrane. E, The myoepithelial marker, p63, was stained. 
Arrowheads indicate a region lost myoepithelial cells. F, ERα was immunostained. Ratios 
of ERα-positive mammary epithelial cells were analyzed (n=3 mice, one-way ANOVA 
followed by Tukey's test). Scale bars indicate 30 μm. n.s.: not significant. Error bars 
represent standard deviation. In the graphs, crosses with different colors indicated the 















Figure S3 Dysplasia is induced by the combination of E2 administration and DNA-
PK pharmacological inhibition. Related to Figure 1 
Fluorescent images of CK8 and CK5 staining are shown. A DNA-PK inhibitor, NU-7441, 
was administered to wild-type stains, C.B-17/Icr and C57BL/6J, in combination with or 
without E2. Mammary ducts with intraductal and extraductal expansion were quantified 
(n=8 mice, U Mann-Whitney test in each strain). Arrowheads indicate mammary 
epithelial cells in extraductal region. Scale bars indicate 30 μm. *: P<0.05, **: P<0.01. 
Error bars represent standard deviation. In the graphs, crosses with different colors 

























































































Figure S4 Mammary epithelial cell proliferation is observed at day 7 in the dysplasia 
model system. Related to Figure 3 
Ki-67 was stained at 0 h, 12 h 24 h, 5 days and 7 days. Ratios of Ki-67-positive mammary 
epithelial cells were analyzed (n=3 mice, one-way ANOVA followed by Tukey's test). 
Scale bars indicate 30 μm. **: P<0.01. Error bars represent standard deviation. In the 
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Figure S5 Estrogen administration induces Myc expression in vivo in mammary 
epithelial cells. Related to Figure 4 
A, Myc mRNA expression was detected by in situ hybridization. Arrowheads indicate 
Myc-expressing domains. B, Myc expression was detected at day 30. Ratios of Myc-
positive mammary epithelial cells were analyzed (n=3 mice, one-way ANOVA followed 
by Tukey's test). C, Typical images of H&E staining are shown. Arrowheads indicate 
mammary epithelial cells in extraductal region. The table shows ratios of dysplasia (n=6 
mice (one image from each mouse, total 6 images), E2+DMSO 11.38% and E2+KJ 3.96% 
(P=0.623 (vs E2+DMSO)), U Mann-Whitney test). D, ERα expression was detected at 
day 30. Ratios of ERα-positive mammary epithelial cells are analyzed (n=3 mice, 
student's t-test). KJ: KJ-Pyr-9. Scale bars indicate 30 μm (A-D). n.s.: not significant, **: 
P<0.01. Error bars represent standard deviation. In the graphs, crosses with different 






































































































































































Figure S6 Isoflavones inhibit estrogen-induced cell proliferation in the mammary 
gland. Related to Figure 5 
A, Typical images of PCNA staining are shown. Quantification is shown in Fig. 5C. B, 
Typical images of Carmine Alum-staining are shown. Numbers of branching are graphed 
in Fig. 5D. C, Gamma-H2AX was stained. Ratios of gH2AX-positive mammary 
epithelial cells are graphed in Fig. 5G. D, Myc immunostaining was performed. Ratios of 
Myc-positive mammary epithelial cells are shown in Fig. 5H. Eq.: (S)-equol, Ge.: 
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Table S1 Frequency of dysplasia formation, related to Figure 1, S3 





















C.B-17/Icr WT+E2 30d  10 232 9.68±7.53 0.34±1.09 
C.B-17/Icr Scid+PBS 30d 10 235 9.48±6.89 1.14±1.85 
C.B-17/Icr Scid+E2 30d 10 283 20.65±9.99 5.92±3.80 
     
C.B-17/Icr WT+NU+PBS 30d 8 204 9.91±6.02 1.12±2.10 
C.B-17/Icr WT+NU+E2 30d 8 201 20.35±9.37 6.99±4.87 
C57BL/6J+NU+PBS 30d 8 128 8.40±7.62 0.83±2.35 
C57BL/6J+NU+E2 30d 8 116 21.76±9.29 8.55±6.48 
